Teva Bids $125 Million for Bankrupt BioXcel in IGALMI Acquisition Race
Teva's Stipulated Bankruptcy Auction Benchmark
BioXcel Therapeutics, Inc. (BTAI) filed for Chapter 11 bankruptcy on August 27, 2026, in the Delaware Bankruptcy Court and entered into an asset purchase agreement with a subsidiary of Teva Pharmaceutical Industries Ltd. (TEVA). Teva submitted a $5.75 million cash bid and a $570,000 deposit, with a conditional maximum additional payment of $6.75 million, as the stalking horse bidder in the court-supervised Section 363 auction. This is not a final acquisition but a benchmark to allow higher competitive bids and court approval, preserving the value of BioXcel's technology amid cash exhaustion.
IGALMI's Approved Asset and Phase 3 Expansion
The key asset BXCL501, branded as IGALMI, contains dexmedetomidine and targets the selective alpha-2 adrenergic receptor as a sublingual film. The FDA approved it on April 5, 2022, for the treatment of acute agitation in adults with schizophrenia and bipolar I and II disorders under medical supervision. The SERENITY At-Home pivotal Phase 3 trial, completed in 2025, met its at-home repeat-dose safety objective. The FDA accepted the supplemental New Drug Application (sNDA) for at-home use on April 1, 2026, with a target action date set for November 14, 2026.
Transaction Economics Linked to Approval Timeline
If the at-home indication is approved by the FDA decision date, the maximum regulatory and commercial milestone payment of $6.75 million will be triggered, making the total potential value $125 million. If the FDA decision is delayed but the approval is granted by February 27, 2027, the milestone payment will be $5.5 million, with reduced regulatory payments and sales-linked terms for later approvals. No royalties or equity investments were disclosed, and the 2025 IGALMI sales of $642,000 indicate the transaction is priced on the commercial expansion potential of the at-home label rather than current revenue.
$6.05 Billion Market and Competitive Landscape
The global acute agitation and aggression treatment market was valued at $6.05 billion in 2025, with company estimates suggesting up to 1.8 million patients and 86 million annual at-home episodes in the U.S. as potential IGALMI targets. Existing approved competitors include olanzapine (Zyprexa), aripiprazole (Abilify), ziprasidone (Geodon) injectables, and loxapine (Adasuve) inhalation. In clinical practice, haloperidol and benzodiazepines are also used. These treatments involve in-hospital administration, sedation, metabolic or extrapyramidal side effects, or dependency risks. Approval of the at-home label could differentiate IGALMI as the first FDA-approved at-home acute agitation treatment.
Teva can strengthen its neuroscience portfolio with IGALMI, already on the market, and the Phase 3-completed at-home expansion rights for up to $125 million, without early-stage research risk. Short-term value hinges on the November 14, 2026, FDA decision and bankruptcy court auction approval, with competitive bids potentially raising the final acquisition price. The U.S. at-home target is up to 1.8 million patients and 86 million annual episodes, with the global acute agitation and aggression treatment market valued at $6.05 billion in 2025. Zyprexa, Abilify, Geodon injectables, and Adasuve inhalation are hospital-focused, so at-home approval would offer a venue-based differentiation. However, BTAI shareholders must consider Chapter 11 distribution priorities and 2025 product sales of $642,000, making an investment decision appropriate for a Watchlist.